Better Therapeutics, Inc.

Better Therapeutics, Inc. is a prescription digital therapeutics company focused on cardiometabolic diseases, including type 2 diabetes and heart failure, that reached the public markets through a SPAC combination in 2021 under the blank-check ticker MCAD on Nasdaq. The company develops software-based therapies designed to treat the behavioral and physiological drivers of cardiometabolic conditions. An 8-K filing dated November 3, 2021, bearing accession number 0001193125-21-318651, reported material corporate developments associated with the transaction or early post-combination operations. The deal was among the wave of digital health SPAC mergers that closed during the active 2021 market cycle. Sign up for full data on SpacDesk to access complete filing history, sponsor details, and real-time SPAC analytics.